US Regulators Approve ‘Game-Changing’ Type 1 Diabetes Drug

Type 1 diabetes affects about 8.7 million people around the world.

  • A new immunotherapy drug that delays the development of type 1 diabetes was given the green light by U.S. regulators.
  • Teplizumab focuses on addressing the root cause of the condition, rather than the symptoms, which experts say ushers in a “new era” in treatment.
  • The drug works by reprogramming the body’s immune system and preventing it from mistakenly attacking pancreatic cells, which produce insulin.
Click to read full article Go back home

Sign Up for Our Newsletter

Join our list!

Sign up here to get our daily newsletter with the top trending headlines.